HB0017NCT06592274
A Phase 2 Study of HB0017 in Psoriasis Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 13 words Show 6 more changesShow less
- Primary endpoints: details revised at 1 of 2 entries
- Trial completed
- Study completion date changed from estimate of Jan 30, 2026 to Apr 10, 2026
- Enrollment target: estimated 200 to confirmed 206
- Secondary endpoints: details revised at 1 of 4 entries
- Site details revised at 18 of 18 sites
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Study sites: 1 to 18
- Primary completion date changed from estimate of Apr 2025 to Apr 30, 2025
- Study completion date: Jan 2026 to Jan 30, 2026
- Study title shortened, about 9 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proportion of subjects achieving PASI 90 response
Timeframe: Week 12
Proportion of subjects achieving sPGA 0/1
Timeframe: Week 12
Secondary (4)
Proportion of subjects achieving PASI 75 response
Proportion of subjects achieving PASI 100 response
PASI 90 response maintainance at week 48
sPGA 0/1 response maintainance at week 48
Arms and interventions
Experimental Group 1Experimental
HB0017 higer dose plus longer dose regimen
Experimental Group 2Experimental
HB0017 higer dose plus shorter dose regimen
Experimental Group 3Experimental
HB0017 low dose plus shortest dose regimen
Biologicals: HB0017
Sites
18 sites in 1 country